Genomics & Screening Core Facility

 
By integrating state-of-the-art equipment and technical expertise, the NUI Galway Genomics & Screening Core Facility has been established in Biomedical Sciences to provide a central resource for academic and industrial research groups looking to quickly expand and advance their current research.
 
Automated high-throughput and high-content discovery tools enable conventional cell-based biological reporter assays to systematically test large numbers of compounds, extracts or genes in a faster, more reliable and less expensive way than is possible manually, while providing a platform for novel assay development to interrogate model systems in new ways.
 
The Core also facilitates the characterisation of gene and protein functions and interactions through access to cutting edge single cell analysis tools, multiplexing instruments for biochemical assays, and a range of qPCR systems.
 
Capabilities
 
 
Drug Discovery & Characterisation
 
High Content Imaging
 
Cell-based assays
 
Enzyme-based assays
 
Environmental Sample Analysis
 
Single Cell Analysis
 
Quantitative Real-Time PCR (qPCR) 
Equipment

 
 
 
 
 
 
 
 
 
 

InDrop Single Cell Analysis System
 
Chemical Compound Libraries
 
BigNeat Compund Storage Cabinet
 
Class II Biosafety Cabinet

Assays

Automated Assays Developed and In Development


Cell Viability (Resazurin, Hoechst, Sulforhodamine B and MTT assays)
 
High Content Immunofluorescent Centrosome Amplification analysis
 
In-Cell Western Protein analysis
 
Cytokine analysis (ELISA assays)
 
Biomaterials analysis
 
Immune Response (Flow Cytometry)
 
Stem Cell analysis (Alkaline Phosphotase and Calcium assays)
 
Genotoxicity analysis (Ames and Clastogenicity assays
 
Quantitative RT-PCR setup
Case Studies
Publications

 
Post-traumatic immunosuppression is reversed by anti-coagulated salvaged blood transfusion: deductions from studying immune status after knee arthroplasty. Islam N, Whitehouse M, Mehendale S, Hall M, Tierney J, O'Connell E, Blom A, Bannister G, Hinde J, Ceredig R, Bradley BA. Clin Exp Immunol. 2014 Aug;177(2):509-20. doi: 10.1111/cei.12351. PubMed PMID: 24749651.

Inhibition of protein synthesis and JNK activation are not required for cell death induced by anisomycin and anisomycin analogues. Monaghan D, O'Connell E, Cruickshank FL, O'Sullivan B, Giles FJ, Hulme AN, Fearnhead HO. Biochem Biophys Res Commun. 2014 Jan 10;443(2):761-7. doi: 10.1016/j.bbrc.2013.12.041. Epub 2013 Dec 12. PubMed PMID: 24333448.
 
A high through-put screen for small molecules modulating MCM2 phosphorylation identifies Ryuvidine as an inducer of the DNA damage response. FitzGerald J, Murillo LS, O'Brien G, O'Connell E, O'Connor A, Wu K, Wang GN, Rainey MD, Natoni A, Healy S, O'Dwyer M, Santocanale C. PLoS One. 2014 Jun 5;9(6):e98891. doi: 10.1371/journal.pone.0098891. eCollection 2014. PubMed PMID: 24902048; PubMed Central PMCID: PMC4047068.

The novel toluidine sulphonamide EL102 shows pre-clinical in vitro and in vivo activity against prostate cancer and circumvents MDR1 resistance. Toner AP, McLaughlin F, Giles FJ, Sullivan FJ, O'Connell E, Carleton LA, Breen L, Dunne G, Gorman AM, Lewis JD, Glynn SA. Br J Cancer. 2013 Oct 15;109(8):2131-41. doi: 10.1038/bjc.2013.537. Epub 2013 Sep 19. PubMed PMID: 24052043; PubMed Central PMCID: PMC3798953.
Training
Useful Links Contact Information
Dr. Enda O'Connell
Screening Core Facility Manager
Email: enda.oconnell@nuigalway.ie
Telephone: +353 91 495435
 
Screening Core Director
Lecturer in Pharmacology and Therapeutics
Principal Investigator in the Apoptosis Research Centre
Email: howard.fearnhead@nuigalway.ie
Telephone: +353 91 495240